BAH vs GNRC

The Advanced Deterministic Scorecard reveals a mixed financial profile for BAH, with a weak Piotroski F-Score of 4/9 indicating marginal financial health, and no available Altman Z-Score to assess distress risk. Despite strong historical ROE of 75.2% and solid cash flow generation, the company faces significant headwinds with declining revenue and earnings, reflected in negative YoY growth of -8.1% and -52.9%, respectively. Valuation metrics suggest the stock is trading above its Graham Number of $35.57 and growth-based intrinsic value of $49.0, yet at a discount to sector peers on P/E. Analysts have a consensus 'hold' rating with a target price of $102.91, nearly at current levels, while technical trend signals remain bearish.

GNRC exhibits a severe disconnect between its current market price ($220.30) and its deterministic value markers, with a Piotroski F-Score of 4/9 indicating only stable health and a Graham Number of $52.11 suggesting massive overvaluation. While the balance sheet remains healthy with low debt and a strong current ratio, the company is facing significant headwinds including negative revenue growth (-11.60%) and a plummeting YoY EPS (-42.5%). The bearish sentiment is further reinforced by aggressive insider selling from the CEO and CFO and a very weak technical trend (10/100). Despite bullish analyst targets, the fundamental data suggests the stock is trading on speculative recovery rather than current performance.